clinical trial · NCT04757610
OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)
Neovascular Age-related Macular Degeneration2.0 mg OPT-3020.5 mg ranibizumabSham
brief summary
A 2-year, phase 3, multicentre, randomised, parallel-group, sham-controlled, double-masked study. Primary efficacy will be determined at Week 52.
started
Mar 12, 2021
primary completion
Mar 31, 2025
completion
Mar 31, 2025
last updated
Jul 22, 2025
official title
A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With nAMD
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol